Home / Health / Newborns' DNA screened for rare diseases
Newborns' DNA screened for rare diseases
24 Jan
Summary
- Babies' full genomes will be screened for hundreds of rare, treatable diseases.
- Study aims to identify conditions like spinal muscular atrophy and MLD early.
- Participation is voluntary, with potential for earlier treatment and life-changing information.
A significant new study is set to revolutionize infant healthcare by screening babies' entire genomes for rare diseases. Led by Dr. Uma Rajesh at Hull Royal Infirmary and involving more than 40 NHS trusts, the initiative offers expectant parents the opportunity to learn about their baby's health at a very early stage.
The study focuses on identifying hundreds of rare, treatable conditions, such as spinal muscular atrophy and metachromatic leukodystrophy (MLD), within a baby's first years. This advanced genomic screening aims to detect these issues much sooner than traditional methods.
Participation in the study is entirely voluntary. Parents-to-be will be informed about the research during pregnancy and offered further details by a research midwife if interested. This early detection holds the potential to enable families to begin crucial treatments sooner, offering a better outlook for affected infants.
